This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

James Ernst, Ph.D.
Vice President, Head of Development Sciences at Xencor
Speaker

Profile


James Ernst received his Ph.D. in Biophysical Chemistry from Yale University and took post-Doctoral Studies in Molecular and Cell Biology at the Stanford University Medical School. He is currently the Head of Development at Xencor Inc. were he leads efforts to translate molecules from late stage research into clinical development. Prior to joining Xencor, he held various leadership positions in the Genentech Research and Early Development (gRED) Protein Sciences division. He has more than 17 years of experience supporting all stages of therapeutic development from target identification to clinical validation. He is an expert in biochemical assay development, protein-protein binding, structure function relationships and antibody production. He has worked with and lead both large and small molecule therapeutic discovery teams a variety of therapeutic areas including oncology immunotherapy, neuroscience and metabolic disease.